nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—KIT—testicular cancer	0.46	1	CbGaD
Dasatinib—ABCG2—Dactinomycin—testicular cancer	0.0226	0.134	CbGbCtD
Dasatinib—CYP1B1—Doxorubicin—testicular cancer	0.0183	0.109	CbGbCtD
Dasatinib—ABCG2—Carboplatin—testicular cancer	0.0152	0.0903	CbGbCtD
Dasatinib—CYP3A5—Ifosfamide—testicular cancer	0.0148	0.0879	CbGbCtD
Dasatinib—ABCG2—Cisplatin—testicular cancer	0.013	0.0772	CbGbCtD
Dasatinib—ABCG2—Etoposide—testicular cancer	0.0128	0.0758	CbGbCtD
Dasatinib—ABCG2—Doxorubicin—testicular cancer	0.0087	0.0517	CbGbCtD
Dasatinib—ABCG2—Methotrexate—testicular cancer	0.00843	0.0501	CbGbCtD
Dasatinib—ABCB1—Dactinomycin—testicular cancer	0.00815	0.0484	CbGbCtD
Dasatinib—CYP3A5—Etoposide—testicular cancer	0.00707	0.042	CbGbCtD
Dasatinib—CYP3A4—Ifosfamide—testicular cancer	0.00577	0.0343	CbGbCtD
Dasatinib—CYP1A2—Etoposide—testicular cancer	0.00526	0.0313	CbGbCtD
Dasatinib—ABCB1—Vinblastine—testicular cancer	0.0051	0.0303	CbGbCtD
Dasatinib—ABCB1—Cisplatin—testicular cancer	0.00468	0.0278	CbGbCtD
Dasatinib—ABCB1—Etoposide—testicular cancer	0.0046	0.0273	CbGbCtD
Dasatinib—KIT—seminiferous tubule of testis—testicular cancer	0.00412	0.0402	CbGeAlD
Dasatinib—ABCB1—Doxorubicin—testicular cancer	0.00314	0.0186	CbGbCtD
Dasatinib—CYP3A4—Vinblastine—testicular cancer	0.00306	0.0182	CbGbCtD
Dasatinib—ABCB1—Methotrexate—testicular cancer	0.00304	0.0181	CbGbCtD
Dasatinib—CYP3A4—Etoposide—testicular cancer	0.00276	0.0164	CbGbCtD
Dasatinib—CYP3A4—Doxorubicin—testicular cancer	0.00188	0.0112	CbGbCtD
Dasatinib—STAT5B—embryo—testicular cancer	0.0014	0.0136	CbGeAlD
Dasatinib—MYT1—testis—testicular cancer	0.00138	0.0134	CbGeAlD
Dasatinib—TEC—testis—testicular cancer	0.00117	0.0114	CbGeAlD
Dasatinib—ZAK—seminal vesicle—testicular cancer	0.0011	0.0107	CbGeAlD
Dasatinib—PKMYT1—gonad—testicular cancer	0.0011	0.0107	CbGeAlD
Dasatinib—FRK—gonad—testicular cancer	0.0011	0.0107	CbGeAlD
Dasatinib—EPHB1—female gonad—testicular cancer	0.00104	0.0101	CbGeAlD
Dasatinib—EPHB3—embryo—testicular cancer	0.00102	0.00992	CbGeAlD
Dasatinib—TESK1—seminal vesicle—testicular cancer	0.000971	0.00947	CbGeAlD
Dasatinib—STK36—seminal vesicle—testicular cancer	0.000955	0.00932	CbGeAlD
Dasatinib—STAT5B—gonad—testicular cancer	0.000949	0.00926	CbGeAlD
Dasatinib—CSK—embryo—testicular cancer	0.000947	0.00923	CbGeAlD
Dasatinib—EPHB1—testis—testicular cancer	0.000919	0.00896	CbGeAlD
Dasatinib—CSK—seminal vesicle—testicular cancer	0.000889	0.00867	CbGeAlD
Dasatinib—HCK—seminal vesicle—testicular cancer	0.000878	0.00856	CbGeAlD
Dasatinib—SIK3—gonad—testicular cancer	0.000853	0.00832	CbGeAlD
Dasatinib—EPHA4—embryo—testicular cancer	0.000849	0.00828	CbGeAlD
Dasatinib—TEC—lymph node—testicular cancer	0.000849	0.00828	CbGeAlD
Dasatinib—ERBB3—embryo—testicular cancer	0.000841	0.0082	CbGeAlD
Dasatinib—RIPK2—seminal vesicle—testicular cancer	0.000825	0.00805	CbGeAlD
Dasatinib—PTK6—female gonad—testicular cancer	0.000816	0.00796	CbGeAlD
Dasatinib—PKMYT1—testis—testicular cancer	0.000791	0.00772	CbGeAlD
Dasatinib—FRK—testis—testicular cancer	0.000791	0.00772	CbGeAlD
Dasatinib—MAPK14—embryo—testicular cancer	0.000783	0.00764	CbGeAlD
Dasatinib—FGR—embryo—testicular cancer	0.00078	0.00761	CbGeAlD
Dasatinib—STAT5B—female gonad—testicular cancer	0.000771	0.00752	CbGeAlD
Dasatinib—JAK2—embryo—testicular cancer	0.000737	0.00719	CbGeAlD
Dasatinib—FGR—seminal vesicle—testicular cancer	0.000733	0.00715	CbGeAlD
Dasatinib—TXK—testis—testicular cancer	0.000731	0.00713	CbGeAlD
Dasatinib—FYN—embryo—testicular cancer	0.000727	0.00709	CbGeAlD
Dasatinib—EPHA8—testis—testicular cancer	0.000723	0.00706	CbGeAlD
Dasatinib—TESK1—gonad—testicular cancer	0.000701	0.00684	CbGeAlD
Dasatinib—EPHB4—seminal vesicle—testicular cancer	0.000697	0.0068	CbGeAlD
Dasatinib—SIK3—female gonad—testicular cancer	0.000693	0.00676	CbGeAlD
Dasatinib—JAK2—seminal vesicle—testicular cancer	0.000692	0.00675	CbGeAlD
Dasatinib—STK36—gonad—testicular cancer	0.00069	0.00673	CbGeAlD
Dasatinib—STAT5B—testis—testicular cancer	0.000684	0.00667	CbGeAlD
Dasatinib—EPHA2—seminal vesicle—testicular cancer	0.000684	0.00667	CbGeAlD
Dasatinib—FYN—seminal vesicle—testicular cancer	0.000683	0.00666	CbGeAlD
Dasatinib—MAP4K5—seminal vesicle—testicular cancer	0.000667	0.00651	CbGeAlD
Dasatinib—MAP3K3—seminal vesicle—testicular cancer	0.000667	0.00651	CbGeAlD
Dasatinib—LIMK2—gonad—testicular cancer	0.000667	0.00651	CbGeAlD
Dasatinib—EPHB1—lymph node—testicular cancer	0.000666	0.0065	CbGeAlD
Dasatinib—STK35—gonad—testicular cancer	0.000647	0.00631	CbGeAlD
Dasatinib—ZAK—female gonad—testicular cancer	0.000645	0.00629	CbGeAlD
Dasatinib—PDGFRA—embryo—testicular cancer	0.000644	0.00628	CbGeAlD
Dasatinib—CSK—gonad—testicular cancer	0.000642	0.00627	CbGeAlD
Dasatinib—EPHB6—seminal vesicle—testicular cancer	0.000638	0.00622	CbGeAlD
Dasatinib—ERBB3—Podofilox—Etoposide—testicular cancer	0.000634	0.209	CbGdCrCtD
Dasatinib—EPHA3—testis—testicular cancer	0.000632	0.00617	CbGeAlD
Dasatinib—SRC—embryo—testicular cancer	0.000631	0.00616	CbGeAlD
Dasatinib—BMPR1B—female gonad—testicular cancer	0.000618	0.00603	CbGeAlD
Dasatinib—YES1—seminal vesicle—testicular cancer	0.000616	0.00601	CbGeAlD
Dasatinib—SIK3—testis—testicular cancer	0.000615	0.006	CbGeAlD
Dasatinib—BTK—female gonad—testicular cancer	0.000615	0.006	CbGeAlD
Dasatinib—TNK2—female gonad—testicular cancer	0.000606	0.00591	CbGeAlD
Dasatinib—SIK1—gonad—testicular cancer	0.000582	0.00568	CbGeAlD
Dasatinib—EPHA4—gonad—testicular cancer	0.000576	0.00562	CbGeAlD
Dasatinib—ZAK—testis—testicular cancer	0.000572	0.00558	CbGeAlD
Dasatinib—TESK1—female gonad—testicular cancer	0.00057	0.00556	CbGeAlD
Dasatinib—CSF1R—embryo—testicular cancer	0.000567	0.00553	CbGeAlD
Dasatinib—MAP3K2—gonad—testicular cancer	0.000565	0.00551	CbGeAlD
Dasatinib—STK36—female gonad—testicular cancer	0.000561	0.00547	CbGeAlD
Dasatinib—EPHB3—female gonad—testicular cancer	0.000561	0.00547	CbGeAlD
Dasatinib—BMX—lymph node—testicular cancer	0.00056	0.00546	CbGeAlD
Dasatinib—BLK—lymph node—testicular cancer	0.000553	0.0054	CbGeAlD
Dasatinib—BMPR1B—testis—testicular cancer	0.000548	0.00535	CbGeAlD
Dasatinib—MAP3K19—testis—testicular cancer	0.000548	0.00535	CbGeAlD
Dasatinib—BTK—testis—testicular cancer	0.000546	0.00532	CbGeAlD
Dasatinib—MAP2K5—seminal vesicle—testicular cancer	0.000545	0.00532	CbGeAlD
Dasatinib—LIMK2—female gonad—testicular cancer	0.000542	0.00529	CbGeAlD
Dasatinib—TNK2—testis—testicular cancer	0.000538	0.00524	CbGeAlD
Dasatinib—CSF1R—seminal vesicle—testicular cancer	0.000532	0.00519	CbGeAlD
Dasatinib—TXK—lymph node—testicular cancer	0.00053	0.00517	CbGeAlD
Dasatinib—STK35—female gonad—testicular cancer	0.000526	0.00513	CbGeAlD
Dasatinib—CSK—female gonad—testicular cancer	0.000522	0.00509	CbGeAlD
Dasatinib—HCK—female gonad—testicular cancer	0.000515	0.00503	CbGeAlD
Dasatinib—KIT—embryo—testicular cancer	0.000515	0.00502	CbGeAlD
Dasatinib—ABL2—female gonad—testicular cancer	0.000512	0.005	CbGeAlD
Dasatinib—TESK1—testis—testicular cancer	0.000505	0.00493	CbGeAlD
Dasatinib—PDGFRB—embryo—testicular cancer	0.000503	0.0049	CbGeAlD
Dasatinib—JAK2—gonad—testicular cancer	0.0005	0.00488	CbGeAlD
Dasatinib—STK36—testis—testicular cancer	0.000497	0.00485	CbGeAlD
Dasatinib—EPHB3—testis—testicular cancer	0.000497	0.00485	CbGeAlD
Dasatinib—STAT5B—lymph node—testicular cancer	0.000496	0.00484	CbGeAlD
Dasatinib—RIPK2—female gonad—testicular cancer	0.000485	0.00473	CbGeAlD
Dasatinib—KIT—seminal vesicle—testicular cancer	0.000483	0.00471	CbGeAlD
Dasatinib—MAP3K3—gonad—testicular cancer	0.000482	0.0047	CbGeAlD
Dasatinib—MAP4K5—gonad—testicular cancer	0.000482	0.0047	CbGeAlD
Dasatinib—LIMK2—testis—testicular cancer	0.000481	0.00469	CbGeAlD
Dasatinib—SIK1—female gonad—testicular cancer	0.000473	0.00462	CbGeAlD
Dasatinib—PDGFRB—seminal vesicle—testicular cancer	0.000472	0.0046	CbGeAlD
Dasatinib—EPHA4—female gonad—testicular cancer	0.000468	0.00457	CbGeAlD
Dasatinib—STK35—testis—testicular cancer	0.000466	0.00455	CbGeAlD
Dasatinib—ERBB3—female gonad—testicular cancer	0.000464	0.00452	CbGeAlD
Dasatinib—CSK—testis—testicular cancer	0.000463	0.00452	CbGeAlD
Dasatinib—MAP3K2—female gonad—testicular cancer	0.000459	0.00448	CbGeAlD
Dasatinib—EPHA3—lymph node—testicular cancer	0.000458	0.00447	CbGeAlD
Dasatinib—HCK—testis—testicular cancer	0.000457	0.00446	CbGeAlD
Dasatinib—ABL2—testis—testicular cancer	0.000454	0.00443	CbGeAlD
Dasatinib—ABL1—embryo—testicular cancer	0.000448	0.00437	CbGeAlD
Dasatinib—SIK3—lymph node—testicular cancer	0.000446	0.00435	CbGeAlD
Dasatinib—YES1—gonad—testicular cancer	0.000445	0.00434	CbGeAlD
Dasatinib—PDGFRA—gonad—testicular cancer	0.000437	0.00426	CbGeAlD
Dasatinib—MAPK14—female gonad—testicular cancer	0.000432	0.00421	CbGeAlD
Dasatinib—FGR—female gonad—testicular cancer	0.00043	0.0042	CbGeAlD
Dasatinib—LCK—female gonad—testicular cancer	0.00043	0.0042	CbGeAlD
Dasatinib—RIPK2—testis—testicular cancer	0.00043	0.00419	CbGeAlD
Dasatinib—SRC—gonad—testicular cancer	0.000428	0.00418	CbGeAlD
Dasatinib—ABL1—seminal vesicle—testicular cancer	0.000421	0.0041	CbGeAlD
Dasatinib—SIK1—testis—testicular cancer	0.00042	0.00409	CbGeAlD
Dasatinib—EPHA4—testis—testicular cancer	0.000415	0.00405	CbGeAlD
Dasatinib—ZAK—lymph node—testicular cancer	0.000414	0.00404	CbGeAlD
Dasatinib—ERBB3—testis—testicular cancer	0.000411	0.00401	CbGeAlD
Dasatinib—EPHB4—female gonad—testicular cancer	0.000409	0.00399	CbGeAlD
Dasatinib—MAP3K2—testis—testicular cancer	0.000407	0.00397	CbGeAlD
Dasatinib—JAK2—female gonad—testicular cancer	0.000407	0.00397	CbGeAlD
Dasatinib—EPHA2—female gonad—testicular cancer	0.000402	0.00392	CbGeAlD
Dasatinib—FYN—female gonad—testicular cancer	0.000401	0.00391	CbGeAlD
Dasatinib—BMPR1B—lymph node—testicular cancer	0.000397	0.00388	CbGeAlD
Dasatinib—BTK—lymph node—testicular cancer	0.000395	0.00386	CbGeAlD
Dasatinib—MAP3K3—female gonad—testicular cancer	0.000392	0.00382	CbGeAlD
Dasatinib—MAP4K5—female gonad—testicular cancer	0.000392	0.00382	CbGeAlD
Dasatinib—TNK2—lymph node—testicular cancer	0.00039	0.0038	CbGeAlD
Dasatinib—CSF1R—gonad—testicular cancer	0.000385	0.00375	CbGeAlD
Dasatinib—MAPK14—testis—testicular cancer	0.000383	0.00374	CbGeAlD
Dasatinib—FGR—testis—testicular cancer	0.000382	0.00372	CbGeAlD
Dasatinib—LCK—testis—testicular cancer	0.000382	0.00372	CbGeAlD
Dasatinib—EPHB6—female gonad—testicular cancer	0.000374	0.00365	CbGeAlD
Dasatinib—FMO3—testis—testicular cancer	0.000368	0.00359	CbGeAlD
Dasatinib—TESK1—lymph node—testicular cancer	0.000366	0.00357	CbGeAlD
Dasatinib—EPHB4—testis—testicular cancer	0.000363	0.00354	CbGeAlD
Dasatinib—YES1—female gonad—testicular cancer	0.000362	0.00353	CbGeAlD
Dasatinib—JAK2—testis—testicular cancer	0.000361	0.00352	CbGeAlD
Dasatinib—STK36—lymph node—testicular cancer	0.000361	0.00352	CbGeAlD
Dasatinib—EPHB3—lymph node—testicular cancer	0.000361	0.00352	CbGeAlD
Dasatinib—EPHA2—testis—testicular cancer	0.000356	0.00348	CbGeAlD
Dasatinib—FYN—testis—testicular cancer	0.000356	0.00347	CbGeAlD
Dasatinib—PDGFRA—female gonad—testicular cancer	0.000355	0.00346	CbGeAlD
Dasatinib—KIT—gonad—testicular cancer	0.000349	0.00341	CbGeAlD
Dasatinib—LIMK2—lymph node—testicular cancer	0.000349	0.0034	CbGeAlD
Dasatinib—SRC—female gonad—testicular cancer	0.000348	0.0034	CbGeAlD
Dasatinib—MAP4K5—testis—testicular cancer	0.000348	0.00339	CbGeAlD
Dasatinib—MAP3K3—testis—testicular cancer	0.000348	0.00339	CbGeAlD
Dasatinib—PDGFRB—gonad—testicular cancer	0.000341	0.00333	CbGeAlD
Dasatinib—STK35—lymph node—testicular cancer	0.000338	0.0033	CbGeAlD
Dasatinib—CSK—lymph node—testicular cancer	0.000336	0.00327	CbGeAlD
Dasatinib—EPHB6—testis—testicular cancer	0.000332	0.00324	CbGeAlD
Dasatinib—HCK—lymph node—testicular cancer	0.000331	0.00323	CbGeAlD
Dasatinib—ABL2—lymph node—testicular cancer	0.000329	0.00321	CbGeAlD
Dasatinib—YES1—testis—testicular cancer	0.000321	0.00313	CbGeAlD
Dasatinib—MAP2K5—female gonad—testicular cancer	0.00032	0.00312	CbGeAlD
Dasatinib—PDGFRA—testis—testicular cancer	0.000315	0.00307	CbGeAlD
Dasatinib—CSF1R—female gonad—testicular cancer	0.000313	0.00305	CbGeAlD
Dasatinib—RIPK2—lymph node—testicular cancer	0.000312	0.00304	CbGeAlD
Dasatinib—SRC—testis—testicular cancer	0.000309	0.00301	CbGeAlD
Dasatinib—CSK—Doxorubicin—Epirubicin—testicular cancer	0.000305	0.1	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Epirubicin—testicular cancer	0.000305	0.1	CbGdCrCtD
Dasatinib—SIK1—lymph node—testicular cancer	0.000304	0.00297	CbGeAlD
Dasatinib—ABL1—gonad—testicular cancer	0.000304	0.00297	CbGeAlD
Dasatinib—EPHA4—lymph node—testicular cancer	0.000301	0.00294	CbGeAlD
Dasatinib—ERBB3—lymph node—testicular cancer	0.000298	0.00291	CbGeAlD
Dasatinib—MAP3K2—lymph node—testicular cancer	0.000295	0.00288	CbGeAlD
Dasatinib—MAP2K5—testis—testicular cancer	0.000284	0.00277	CbGeAlD
Dasatinib—KIT—female gonad—testicular cancer	0.000284	0.00277	CbGeAlD
Dasatinib—CSK—Epirubicin—Doxorubicin—testicular cancer	0.000283	0.0929	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Doxorubicin—testicular cancer	0.000283	0.0929	CbGdCrCtD
Dasatinib—MAPK14—lymph node—testicular cancer	0.000278	0.00271	CbGeAlD
Dasatinib—CSF1R—testis—testicular cancer	0.000277	0.0027	CbGeAlD
Dasatinib—PDGFRB—female gonad—testicular cancer	0.000277	0.0027	CbGeAlD
Dasatinib—FGR—lymph node—testicular cancer	0.000277	0.0027	CbGeAlD
Dasatinib—LCK—lymph node—testicular cancer	0.000277	0.0027	CbGeAlD
Dasatinib—FMO3—lymph node—testicular cancer	0.000267	0.00261	CbGeAlD
Dasatinib—ABCG2—seminal vesicle—testicular cancer	0.000265	0.00259	CbGeAlD
Dasatinib—EPHB4—lymph node—testicular cancer	0.000263	0.00257	CbGeAlD
Dasatinib—JAK2—lymph node—testicular cancer	0.000261	0.00255	CbGeAlD
Dasatinib—EPHA2—lymph node—testicular cancer	0.000258	0.00252	CbGeAlD
Dasatinib—FYN—lymph node—testicular cancer	0.000258	0.00251	CbGeAlD
Dasatinib—CYP1B1—gonad—testicular cancer	0.000257	0.00251	CbGeAlD
Dasatinib—MAP4K5—lymph node—testicular cancer	0.000252	0.00246	CbGeAlD
Dasatinib—MAP3K3—lymph node—testicular cancer	0.000252	0.00246	CbGeAlD
Dasatinib—KIT—testis—testicular cancer	0.000252	0.00246	CbGeAlD
Dasatinib—ABL1—female gonad—testicular cancer	0.000247	0.00241	CbGeAlD
Dasatinib—PDGFRB—testis—testicular cancer	0.000246	0.0024	CbGeAlD
Dasatinib—EPHB6—lymph node—testicular cancer	0.000241	0.00235	CbGeAlD
Dasatinib—YES1—lymph node—testicular cancer	0.000233	0.00227	CbGeAlD
Dasatinib—PDGFRA—lymph node—testicular cancer	0.000228	0.00223	CbGeAlD
Dasatinib—SRC—lymph node—testicular cancer	0.000224	0.00218	CbGeAlD
Dasatinib—ABL1—testis—testicular cancer	0.000219	0.00214	CbGeAlD
Dasatinib—ABL1—Daunorubicin—Epirubicin—testicular cancer	0.000213	0.0701	CbGdCrCtD
Dasatinib—ABL1—Doxorubicin—Epirubicin—testicular cancer	0.000213	0.0701	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Epirubicin—testicular cancer	0.000213	0.0701	CbGdCrCtD
Dasatinib—CYP1B1—female gonad—testicular cancer	0.000209	0.00204	CbGeAlD
Dasatinib—MAP2K5—lymph node—testicular cancer	0.000206	0.00201	CbGeAlD
Dasatinib—CSF1R—lymph node—testicular cancer	0.000201	0.00196	CbGeAlD
Dasatinib—ABL1—Epirubicin—Doxorubicin—testicular cancer	0.000197	0.0649	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Doxorubicin—testicular cancer	0.000197	0.0649	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Doxorubicin—testicular cancer	0.000197	0.0649	CbGdCrCtD
Dasatinib—CYP1B1—testis—testicular cancer	0.000186	0.00181	CbGeAlD
Dasatinib—KIT—lymph node—testicular cancer	0.000182	0.00178	CbGeAlD
Dasatinib—PDGFRB—lymph node—testicular cancer	0.000178	0.00174	CbGeAlD
Dasatinib—ABL1—lymph node—testicular cancer	0.000159	0.00155	CbGeAlD
Dasatinib—ABCG2—female gonad—testicular cancer	0.000156	0.00152	CbGeAlD
Dasatinib—CYP1A1—female gonad—testicular cancer	0.000148	0.00144	CbGeAlD
Dasatinib—CYP3A5—female gonad—testicular cancer	0.000145	0.00141	CbGeAlD
Dasatinib—ABCB1—embryo—testicular cancer	0.000139	0.00136	CbGeAlD
Dasatinib—ABCG2—testis—testicular cancer	0.000138	0.00135	CbGeAlD
Dasatinib—CYP1B1—lymph node—testicular cancer	0.000135	0.00131	CbGeAlD
Dasatinib—ABCB1—seminal vesicle—testicular cancer	0.000131	0.00128	CbGeAlD
Dasatinib—ABCG2—lymph node—testicular cancer	0.0001	0.000977	CbGeAlD
Dasatinib—CYP1A1—lymph node—testicular cancer	9.51e-05	0.000928	CbGeAlD
Dasatinib—ABCB1—gonad—testicular cancer	9.45e-05	0.000922	CbGeAlD
Dasatinib—ABCB1—female gonad—testicular cancer	7.68e-05	0.000749	CbGeAlD
Dasatinib—ABCB1—testis—testicular cancer	6.81e-05	0.000665	CbGeAlD
Dasatinib—Weight decreased—Doxorubicin—testicular cancer	6.51e-05	0.000436	CcSEcCtD
Dasatinib—Feeling abnormal—Etoposide—testicular cancer	6.5e-05	0.000435	CcSEcCtD
Dasatinib—Nausea—Dactinomycin—testicular cancer	6.48e-05	0.000434	CcSEcCtD
Dasatinib—Pneumonia—Doxorubicin—testicular cancer	6.45e-05	0.000432	CcSEcCtD
Dasatinib—Gastrointestinal pain—Etoposide—testicular cancer	6.45e-05	0.000432	CcSEcCtD
Dasatinib—Infestation NOS—Doxorubicin—testicular cancer	6.42e-05	0.00043	CcSEcCtD
Dasatinib—Infestation—Doxorubicin—testicular cancer	6.42e-05	0.00043	CcSEcCtD
Dasatinib—Visual impairment—Methotrexate—testicular cancer	6.41e-05	0.000429	CcSEcCtD
Dasatinib—Vomiting—Ifosfamide—testicular cancer	6.35e-05	0.000425	CcSEcCtD
Dasatinib—Hypersensitivity—Cisplatin—testicular cancer	6.35e-05	0.000425	CcSEcCtD
Dasatinib—Renal failure—Doxorubicin—testicular cancer	6.31e-05	0.000422	CcSEcCtD
Dasatinib—Rash—Ifosfamide—testicular cancer	6.3e-05	0.000422	CcSEcCtD
Dasatinib—Dermatitis—Ifosfamide—testicular cancer	6.29e-05	0.000421	CcSEcCtD
Dasatinib—Erythema multiforme—Methotrexate—testicular cancer	6.29e-05	0.000421	CcSEcCtD
Dasatinib—Neuropathy peripheral—Doxorubicin—testicular cancer	6.29e-05	0.000421	CcSEcCtD
Dasatinib—Urticaria—Etoposide—testicular cancer	6.27e-05	0.00042	CcSEcCtD
Dasatinib—Haemoglobin—Epirubicin—testicular cancer	6.26e-05	0.000419	CcSEcCtD
Dasatinib—Stomatitis—Doxorubicin—testicular cancer	6.26e-05	0.000419	CcSEcCtD
Dasatinib—Abdominal pain—Etoposide—testicular cancer	6.24e-05	0.000418	CcSEcCtD
Dasatinib—Body temperature increased—Etoposide—testicular cancer	6.24e-05	0.000418	CcSEcCtD
Dasatinib—Conjunctivitis—Doxorubicin—testicular cancer	6.24e-05	0.000418	CcSEcCtD
Dasatinib—Hepatitis—Epirubicin—testicular cancer	6.23e-05	0.000417	CcSEcCtD
Dasatinib—Haemorrhage—Epirubicin—testicular cancer	6.23e-05	0.000417	CcSEcCtD
Dasatinib—Eye disorder—Methotrexate—testicular cancer	6.22e-05	0.000416	CcSEcCtD
Dasatinib—Tinnitus—Methotrexate—testicular cancer	6.2e-05	0.000415	CcSEcCtD
Dasatinib—Asthenia—Cisplatin—testicular cancer	6.18e-05	0.000414	CcSEcCtD
Dasatinib—Cardiac disorder—Methotrexate—testicular cancer	6.17e-05	0.000413	CcSEcCtD
Dasatinib—Urinary tract disorder—Epirubicin—testicular cancer	6.15e-05	0.000412	CcSEcCtD
Dasatinib—Oedema peripheral—Epirubicin—testicular cancer	6.13e-05	0.000411	CcSEcCtD
Dasatinib—Haematuria—Doxorubicin—testicular cancer	6.12e-05	0.00041	CcSEcCtD
Dasatinib—Connective tissue disorder—Epirubicin—testicular cancer	6.12e-05	0.00041	CcSEcCtD
Dasatinib—Urethral disorder—Epirubicin—testicular cancer	6.1e-05	0.000409	CcSEcCtD
Dasatinib—Hepatobiliary disease—Doxorubicin—testicular cancer	6.07e-05	0.000406	CcSEcCtD
Dasatinib—Epistaxis—Doxorubicin—testicular cancer	6.05e-05	0.000405	CcSEcCtD
Dasatinib—Angiopathy—Methotrexate—testicular cancer	6.04e-05	0.000404	CcSEcCtD
Dasatinib—Immune system disorder—Methotrexate—testicular cancer	6.01e-05	0.000402	CcSEcCtD
Dasatinib—Visual impairment—Epirubicin—testicular cancer	6e-05	0.000402	CcSEcCtD
Dasatinib—Mediastinal disorder—Methotrexate—testicular cancer	6e-05	0.000402	CcSEcCtD
Dasatinib—Chills—Methotrexate—testicular cancer	5.97e-05	0.0004	CcSEcCtD
Dasatinib—Nausea—Ifosfamide—testicular cancer	5.93e-05	0.000397	CcSEcCtD
Dasatinib—Diarrhoea—Cisplatin—testicular cancer	5.89e-05	0.000395	CcSEcCtD
Dasatinib—Erythema multiforme—Epirubicin—testicular cancer	5.89e-05	0.000394	CcSEcCtD
Dasatinib—Alopecia—Methotrexate—testicular cancer	5.88e-05	0.000394	CcSEcCtD
Dasatinib—Mental disorder—Methotrexate—testicular cancer	5.83e-05	0.00039	CcSEcCtD
Dasatinib—Eye disorder—Epirubicin—testicular cancer	5.82e-05	0.00039	CcSEcCtD
Dasatinib—Hypersensitivity—Etoposide—testicular cancer	5.81e-05	0.000389	CcSEcCtD
Dasatinib—Tinnitus—Epirubicin—testicular cancer	5.8e-05	0.000389	CcSEcCtD
Dasatinib—Malnutrition—Methotrexate—testicular cancer	5.79e-05	0.000388	CcSEcCtD
Dasatinib—Erythema—Methotrexate—testicular cancer	5.79e-05	0.000388	CcSEcCtD
Dasatinib—Haemoglobin—Doxorubicin—testicular cancer	5.79e-05	0.000388	CcSEcCtD
Dasatinib—Cardiac disorder—Epirubicin—testicular cancer	5.78e-05	0.000387	CcSEcCtD
Dasatinib—Flushing—Epirubicin—testicular cancer	5.78e-05	0.000387	CcSEcCtD
Dasatinib—Hepatitis—Doxorubicin—testicular cancer	5.76e-05	0.000386	CcSEcCtD
Dasatinib—Haemorrhage—Doxorubicin—testicular cancer	5.76e-05	0.000386	CcSEcCtD
Dasatinib—Urinary tract disorder—Doxorubicin—testicular cancer	5.69e-05	0.000381	CcSEcCtD
Dasatinib—Oedema peripheral—Doxorubicin—testicular cancer	5.67e-05	0.00038	CcSEcCtD
Dasatinib—Dysgeusia—Methotrexate—testicular cancer	5.67e-05	0.00038	CcSEcCtD
Dasatinib—Asthenia—Etoposide—testicular cancer	5.66e-05	0.000379	CcSEcCtD
Dasatinib—Connective tissue disorder—Doxorubicin—testicular cancer	5.66e-05	0.000379	CcSEcCtD
Dasatinib—Angiopathy—Epirubicin—testicular cancer	5.65e-05	0.000378	CcSEcCtD
Dasatinib—Urethral disorder—Doxorubicin—testicular cancer	5.65e-05	0.000378	CcSEcCtD
Dasatinib—Immune system disorder—Epirubicin—testicular cancer	5.62e-05	0.000377	CcSEcCtD
Dasatinib—Mediastinal disorder—Epirubicin—testicular cancer	5.61e-05	0.000376	CcSEcCtD
Dasatinib—Chills—Epirubicin—testicular cancer	5.59e-05	0.000374	CcSEcCtD
Dasatinib—Pruritus—Etoposide—testicular cancer	5.58e-05	0.000374	CcSEcCtD
Dasatinib—Arrhythmia—Epirubicin—testicular cancer	5.56e-05	0.000372	CcSEcCtD
Dasatinib—Visual impairment—Doxorubicin—testicular cancer	5.55e-05	0.000372	CcSEcCtD
Dasatinib—Alopecia—Epirubicin—testicular cancer	5.5e-05	0.000368	CcSEcCtD
Dasatinib—Vomiting—Cisplatin—testicular cancer	5.48e-05	0.000367	CcSEcCtD
Dasatinib—Vision blurred—Methotrexate—testicular cancer	5.46e-05	0.000366	CcSEcCtD
Dasatinib—Mental disorder—Epirubicin—testicular cancer	5.45e-05	0.000365	CcSEcCtD
Dasatinib—Erythema multiforme—Doxorubicin—testicular cancer	5.45e-05	0.000365	CcSEcCtD
Dasatinib—Rash—Cisplatin—testicular cancer	5.43e-05	0.000364	CcSEcCtD
Dasatinib—Dermatitis—Cisplatin—testicular cancer	5.43e-05	0.000363	CcSEcCtD
Dasatinib—Malnutrition—Epirubicin—testicular cancer	5.42e-05	0.000363	CcSEcCtD
Dasatinib—Erythema—Epirubicin—testicular cancer	5.42e-05	0.000363	CcSEcCtD
Dasatinib—Diarrhoea—Etoposide—testicular cancer	5.4e-05	0.000362	CcSEcCtD
Dasatinib—Eye disorder—Doxorubicin—testicular cancer	5.38e-05	0.000361	CcSEcCtD
Dasatinib—Ill-defined disorder—Methotrexate—testicular cancer	5.37e-05	0.00036	CcSEcCtD
Dasatinib—Tinnitus—Doxorubicin—testicular cancer	5.37e-05	0.00036	CcSEcCtD
Dasatinib—Anaemia—Methotrexate—testicular cancer	5.35e-05	0.000358	CcSEcCtD
Dasatinib—Flushing—Doxorubicin—testicular cancer	5.35e-05	0.000358	CcSEcCtD
Dasatinib—Cardiac disorder—Doxorubicin—testicular cancer	5.35e-05	0.000358	CcSEcCtD
Dasatinib—Dysgeusia—Epirubicin—testicular cancer	5.31e-05	0.000355	CcSEcCtD
Dasatinib—Angiopathy—Doxorubicin—testicular cancer	5.23e-05	0.00035	CcSEcCtD
Dasatinib—Malaise—Methotrexate—testicular cancer	5.22e-05	0.00035	CcSEcCtD
Dasatinib—Dizziness—Etoposide—testicular cancer	5.22e-05	0.000349	CcSEcCtD
Dasatinib—Muscle spasms—Epirubicin—testicular cancer	5.21e-05	0.000349	CcSEcCtD
Dasatinib—Immune system disorder—Doxorubicin—testicular cancer	5.2e-05	0.000348	CcSEcCtD
Dasatinib—Vertigo—Methotrexate—testicular cancer	5.2e-05	0.000348	CcSEcCtD
Dasatinib—Mediastinal disorder—Doxorubicin—testicular cancer	5.19e-05	0.000348	CcSEcCtD
Dasatinib—Chills—Doxorubicin—testicular cancer	5.17e-05	0.000346	CcSEcCtD
Dasatinib—Arrhythmia—Doxorubicin—testicular cancer	5.15e-05	0.000345	CcSEcCtD
Dasatinib—Nausea—Cisplatin—testicular cancer	5.12e-05	0.000343	CcSEcCtD
Dasatinib—Vision blurred—Epirubicin—testicular cancer	5.11e-05	0.000342	CcSEcCtD
Dasatinib—Alopecia—Doxorubicin—testicular cancer	5.09e-05	0.000341	CcSEcCtD
Dasatinib—Cough—Methotrexate—testicular cancer	5.05e-05	0.000338	CcSEcCtD
Dasatinib—Mental disorder—Doxorubicin—testicular cancer	5.05e-05	0.000338	CcSEcCtD
Dasatinib—Ill-defined disorder—Epirubicin—testicular cancer	5.03e-05	0.000337	CcSEcCtD
Dasatinib—Convulsion—Methotrexate—testicular cancer	5.02e-05	0.000336	CcSEcCtD
Dasatinib—Vomiting—Etoposide—testicular cancer	5.02e-05	0.000336	CcSEcCtD
Dasatinib—Erythema—Doxorubicin—testicular cancer	5.01e-05	0.000336	CcSEcCtD
Dasatinib—Malnutrition—Doxorubicin—testicular cancer	5.01e-05	0.000336	CcSEcCtD
Dasatinib—Anaemia—Epirubicin—testicular cancer	5.01e-05	0.000335	CcSEcCtD
Dasatinib—Rash—Etoposide—testicular cancer	4.98e-05	0.000333	CcSEcCtD
Dasatinib—Dermatitis—Etoposide—testicular cancer	4.97e-05	0.000333	CcSEcCtD
Dasatinib—Headache—Etoposide—testicular cancer	4.94e-05	0.000331	CcSEcCtD
Dasatinib—ABCB1—lymph node—testicular cancer	4.94e-05	0.000482	CbGeAlD
Dasatinib—Myalgia—Methotrexate—testicular cancer	4.93e-05	0.00033	CcSEcCtD
Dasatinib—Arthralgia—Methotrexate—testicular cancer	4.93e-05	0.00033	CcSEcCtD
Dasatinib—Chest pain—Methotrexate—testicular cancer	4.93e-05	0.00033	CcSEcCtD
Dasatinib—Dysgeusia—Doxorubicin—testicular cancer	4.91e-05	0.000329	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	4.9e-05	0.000328	CcSEcCtD
Dasatinib—Malaise—Epirubicin—testicular cancer	4.89e-05	0.000327	CcSEcCtD
Dasatinib—Discomfort—Methotrexate—testicular cancer	4.87e-05	0.000326	CcSEcCtD
Dasatinib—Vertigo—Epirubicin—testicular cancer	4.87e-05	0.000326	CcSEcCtD
Dasatinib—Syncope—Epirubicin—testicular cancer	4.86e-05	0.000325	CcSEcCtD
Dasatinib—Muscle spasms—Doxorubicin—testicular cancer	4.82e-05	0.000323	CcSEcCtD
Dasatinib—Palpitations—Epirubicin—testicular cancer	4.79e-05	0.000321	CcSEcCtD
Dasatinib—Confusional state—Methotrexate—testicular cancer	4.77e-05	0.000319	CcSEcCtD
Dasatinib—Loss of consciousness—Epirubicin—testicular cancer	4.76e-05	0.000319	CcSEcCtD
Dasatinib—Cough—Epirubicin—testicular cancer	4.73e-05	0.000317	CcSEcCtD
Dasatinib—Vision blurred—Doxorubicin—testicular cancer	4.73e-05	0.000316	CcSEcCtD
Dasatinib—Convulsion—Epirubicin—testicular cancer	4.7e-05	0.000314	CcSEcCtD
Dasatinib—Infection—Methotrexate—testicular cancer	4.7e-05	0.000314	CcSEcCtD
Dasatinib—Nausea—Etoposide—testicular cancer	4.69e-05	0.000314	CcSEcCtD
Dasatinib—Hypertension—Epirubicin—testicular cancer	4.68e-05	0.000313	CcSEcCtD
Dasatinib—Ill-defined disorder—Doxorubicin—testicular cancer	4.65e-05	0.000312	CcSEcCtD
Dasatinib—Nervous system disorder—Methotrexate—testicular cancer	4.64e-05	0.00031	CcSEcCtD
Dasatinib—Anaemia—Doxorubicin—testicular cancer	4.63e-05	0.00031	CcSEcCtD
Dasatinib—Thrombocytopenia—Methotrexate—testicular cancer	4.63e-05	0.00031	CcSEcCtD
Dasatinib—Arthralgia—Epirubicin—testicular cancer	4.61e-05	0.000309	CcSEcCtD
Dasatinib—Myalgia—Epirubicin—testicular cancer	4.61e-05	0.000309	CcSEcCtD
Dasatinib—Chest pain—Epirubicin—testicular cancer	4.61e-05	0.000309	CcSEcCtD
Dasatinib—Anxiety—Epirubicin—testicular cancer	4.6e-05	0.000308	CcSEcCtD
Dasatinib—Skin disorder—Methotrexate—testicular cancer	4.59e-05	0.000307	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	4.58e-05	0.000307	CcSEcCtD
Dasatinib—Hyperhidrosis—Methotrexate—testicular cancer	4.57e-05	0.000306	CcSEcCtD
Dasatinib—Discomfort—Epirubicin—testicular cancer	4.56e-05	0.000305	CcSEcCtD
Dasatinib—Malaise—Doxorubicin—testicular cancer	4.52e-05	0.000303	CcSEcCtD
Dasatinib—Vertigo—Doxorubicin—testicular cancer	4.51e-05	0.000302	CcSEcCtD
Dasatinib—Anorexia—Methotrexate—testicular cancer	4.51e-05	0.000302	CcSEcCtD
Dasatinib—Syncope—Doxorubicin—testicular cancer	4.5e-05	0.000301	CcSEcCtD
Dasatinib—Confusional state—Epirubicin—testicular cancer	4.46e-05	0.000299	CcSEcCtD
Dasatinib—Palpitations—Doxorubicin—testicular cancer	4.43e-05	0.000297	CcSEcCtD
Dasatinib—Oedema—Epirubicin—testicular cancer	4.42e-05	0.000296	CcSEcCtD
Dasatinib—Hypotension—Methotrexate—testicular cancer	4.42e-05	0.000296	CcSEcCtD
Dasatinib—Loss of consciousness—Doxorubicin—testicular cancer	4.41e-05	0.000295	CcSEcCtD
Dasatinib—Infection—Epirubicin—testicular cancer	4.39e-05	0.000294	CcSEcCtD
Dasatinib—Cough—Doxorubicin—testicular cancer	4.38e-05	0.000293	CcSEcCtD
Dasatinib—Shock—Epirubicin—testicular cancer	4.35e-05	0.000291	CcSEcCtD
Dasatinib—Convulsion—Doxorubicin—testicular cancer	4.34e-05	0.000291	CcSEcCtD
Dasatinib—Nervous system disorder—Epirubicin—testicular cancer	4.34e-05	0.00029	CcSEcCtD
Dasatinib—Thrombocytopenia—Epirubicin—testicular cancer	4.33e-05	0.00029	CcSEcCtD
Dasatinib—Hypertension—Doxorubicin—testicular cancer	4.33e-05	0.00029	CcSEcCtD
Dasatinib—Tachycardia—Epirubicin—testicular cancer	4.32e-05	0.000289	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Methotrexate—testicular cancer	4.31e-05	0.000288	CcSEcCtD
Dasatinib—Skin disorder—Epirubicin—testicular cancer	4.3e-05	0.000288	CcSEcCtD
Dasatinib—Hyperhidrosis—Epirubicin—testicular cancer	4.28e-05	0.000286	CcSEcCtD
Dasatinib—Insomnia—Methotrexate—testicular cancer	4.27e-05	0.000286	CcSEcCtD
Dasatinib—Myalgia—Doxorubicin—testicular cancer	4.27e-05	0.000286	CcSEcCtD
Dasatinib—Arthralgia—Doxorubicin—testicular cancer	4.27e-05	0.000286	CcSEcCtD
Dasatinib—Chest pain—Doxorubicin—testicular cancer	4.27e-05	0.000286	CcSEcCtD
Dasatinib—Anxiety—Doxorubicin—testicular cancer	4.25e-05	0.000285	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	4.24e-05	0.000284	CcSEcCtD
Dasatinib—Discomfort—Doxorubicin—testicular cancer	4.22e-05	0.000282	CcSEcCtD
Dasatinib—Anorexia—Epirubicin—testicular cancer	4.22e-05	0.000282	CcSEcCtD
Dasatinib—Dyspnoea—Methotrexate—testicular cancer	4.21e-05	0.000282	CcSEcCtD
Dasatinib—Somnolence—Methotrexate—testicular cancer	4.2e-05	0.000281	CcSEcCtD
Dasatinib—Dyspepsia—Methotrexate—testicular cancer	4.16e-05	0.000279	CcSEcCtD
Dasatinib—Hypotension—Epirubicin—testicular cancer	4.13e-05	0.000277	CcSEcCtD
Dasatinib—Confusional state—Doxorubicin—testicular cancer	4.13e-05	0.000276	CcSEcCtD
Dasatinib—Decreased appetite—Methotrexate—testicular cancer	4.11e-05	0.000275	CcSEcCtD
Dasatinib—Oedema—Doxorubicin—testicular cancer	4.09e-05	0.000274	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Methotrexate—testicular cancer	4.08e-05	0.000273	CcSEcCtD
Dasatinib—Fatigue—Methotrexate—testicular cancer	4.07e-05	0.000273	CcSEcCtD
Dasatinib—Infection—Doxorubicin—testicular cancer	4.07e-05	0.000272	CcSEcCtD
Dasatinib—Pain—Methotrexate—testicular cancer	4.04e-05	0.000271	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Epirubicin—testicular cancer	4.03e-05	0.00027	CcSEcCtD
Dasatinib—Shock—Doxorubicin—testicular cancer	4.03e-05	0.00027	CcSEcCtD
Dasatinib—Nervous system disorder—Doxorubicin—testicular cancer	4.01e-05	0.000269	CcSEcCtD
Dasatinib—Thrombocytopenia—Doxorubicin—testicular cancer	4.01e-05	0.000268	CcSEcCtD
Dasatinib—Insomnia—Epirubicin—testicular cancer	4e-05	0.000268	CcSEcCtD
Dasatinib—Tachycardia—Doxorubicin—testicular cancer	3.99e-05	0.000267	CcSEcCtD
Dasatinib—Skin disorder—Doxorubicin—testicular cancer	3.98e-05	0.000266	CcSEcCtD
Dasatinib—Hyperhidrosis—Doxorubicin—testicular cancer	3.96e-05	0.000265	CcSEcCtD
Dasatinib—Dyspnoea—Epirubicin—testicular cancer	3.94e-05	0.000264	CcSEcCtD
Dasatinib—Somnolence—Epirubicin—testicular cancer	3.93e-05	0.000263	CcSEcCtD
Dasatinib—Anorexia—Doxorubicin—testicular cancer	3.9e-05	0.000261	CcSEcCtD
Dasatinib—Feeling abnormal—Methotrexate—testicular cancer	3.89e-05	0.000261	CcSEcCtD
Dasatinib—Dyspepsia—Epirubicin—testicular cancer	3.89e-05	0.000261	CcSEcCtD
Dasatinib—Gastrointestinal pain—Methotrexate—testicular cancer	3.86e-05	0.000259	CcSEcCtD
Dasatinib—Decreased appetite—Epirubicin—testicular cancer	3.85e-05	0.000257	CcSEcCtD
Dasatinib—Hypotension—Doxorubicin—testicular cancer	3.82e-05	0.000256	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Epirubicin—testicular cancer	3.82e-05	0.000256	CcSEcCtD
Dasatinib—Fatigue—Epirubicin—testicular cancer	3.81e-05	0.000255	CcSEcCtD
Dasatinib—Pain—Epirubicin—testicular cancer	3.78e-05	0.000253	CcSEcCtD
Dasatinib—Constipation—Epirubicin—testicular cancer	3.78e-05	0.000253	CcSEcCtD
Dasatinib—Urticaria—Methotrexate—testicular cancer	3.75e-05	0.000251	CcSEcCtD
Dasatinib—Body temperature increased—Methotrexate—testicular cancer	3.74e-05	0.00025	CcSEcCtD
Dasatinib—Abdominal pain—Methotrexate—testicular cancer	3.74e-05	0.00025	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	3.73e-05	0.00025	CcSEcCtD
Dasatinib—Insomnia—Doxorubicin—testicular cancer	3.7e-05	0.000248	CcSEcCtD
Dasatinib—Dyspnoea—Doxorubicin—testicular cancer	3.65e-05	0.000244	CcSEcCtD
Dasatinib—Feeling abnormal—Epirubicin—testicular cancer	3.64e-05	0.000244	CcSEcCtD
Dasatinib—Somnolence—Doxorubicin—testicular cancer	3.64e-05	0.000244	CcSEcCtD
Dasatinib—Gastrointestinal pain—Epirubicin—testicular cancer	3.62e-05	0.000242	CcSEcCtD
Dasatinib—Dyspepsia—Doxorubicin—testicular cancer	3.6e-05	0.000241	CcSEcCtD
Dasatinib—Decreased appetite—Doxorubicin—testicular cancer	3.56e-05	0.000238	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Doxorubicin—testicular cancer	3.53e-05	0.000237	CcSEcCtD
Dasatinib—Fatigue—Doxorubicin—testicular cancer	3.53e-05	0.000236	CcSEcCtD
Dasatinib—Urticaria—Epirubicin—testicular cancer	3.51e-05	0.000235	CcSEcCtD
Dasatinib—Constipation—Doxorubicin—testicular cancer	3.5e-05	0.000234	CcSEcCtD
Dasatinib—Pain—Doxorubicin—testicular cancer	3.5e-05	0.000234	CcSEcCtD
Dasatinib—Body temperature increased—Epirubicin—testicular cancer	3.5e-05	0.000234	CcSEcCtD
Dasatinib—Abdominal pain—Epirubicin—testicular cancer	3.5e-05	0.000234	CcSEcCtD
Dasatinib—Hypersensitivity—Methotrexate—testicular cancer	3.48e-05	0.000233	CcSEcCtD
Dasatinib—Asthenia—Methotrexate—testicular cancer	3.39e-05	0.000227	CcSEcCtD
Dasatinib—Feeling abnormal—Doxorubicin—testicular cancer	3.37e-05	0.000226	CcSEcCtD
Dasatinib—Gastrointestinal pain—Doxorubicin—testicular cancer	3.35e-05	0.000224	CcSEcCtD
Dasatinib—Pruritus—Methotrexate—testicular cancer	3.34e-05	0.000224	CcSEcCtD
Dasatinib—Hypersensitivity—Epirubicin—testicular cancer	3.26e-05	0.000218	CcSEcCtD
Dasatinib—Urticaria—Doxorubicin—testicular cancer	3.25e-05	0.000218	CcSEcCtD
Dasatinib—Abdominal pain—Doxorubicin—testicular cancer	3.24e-05	0.000217	CcSEcCtD
Dasatinib—Body temperature increased—Doxorubicin—testicular cancer	3.24e-05	0.000217	CcSEcCtD
Dasatinib—Diarrhoea—Methotrexate—testicular cancer	3.23e-05	0.000217	CcSEcCtD
Dasatinib—Asthenia—Epirubicin—testicular cancer	3.17e-05	0.000213	CcSEcCtD
Dasatinib—Pruritus—Epirubicin—testicular cancer	3.13e-05	0.00021	CcSEcCtD
Dasatinib—Dizziness—Methotrexate—testicular cancer	3.13e-05	0.000209	CcSEcCtD
Dasatinib—Diarrhoea—Epirubicin—testicular cancer	3.03e-05	0.000203	CcSEcCtD
Dasatinib—Hypersensitivity—Doxorubicin—testicular cancer	3.02e-05	0.000202	CcSEcCtD
Dasatinib—Vomiting—Methotrexate—testicular cancer	3.01e-05	0.000201	CcSEcCtD
Dasatinib—Rash—Methotrexate—testicular cancer	2.98e-05	0.0002	CcSEcCtD
Dasatinib—Dermatitis—Methotrexate—testicular cancer	2.98e-05	0.000199	CcSEcCtD
Dasatinib—Headache—Methotrexate—testicular cancer	2.96e-05	0.000198	CcSEcCtD
Dasatinib—Asthenia—Doxorubicin—testicular cancer	2.94e-05	0.000197	CcSEcCtD
Dasatinib—Dizziness—Epirubicin—testicular cancer	2.92e-05	0.000196	CcSEcCtD
Dasatinib—Pruritus—Doxorubicin—testicular cancer	2.9e-05	0.000194	CcSEcCtD
Dasatinib—Vomiting—Epirubicin—testicular cancer	2.81e-05	0.000188	CcSEcCtD
Dasatinib—Nausea—Methotrexate—testicular cancer	2.81e-05	0.000188	CcSEcCtD
Dasatinib—Diarrhoea—Doxorubicin—testicular cancer	2.8e-05	0.000188	CcSEcCtD
Dasatinib—Rash—Epirubicin—testicular cancer	2.79e-05	0.000187	CcSEcCtD
Dasatinib—Dermatitis—Epirubicin—testicular cancer	2.79e-05	0.000187	CcSEcCtD
Dasatinib—Headache—Epirubicin—testicular cancer	2.77e-05	0.000186	CcSEcCtD
Dasatinib—Dizziness—Doxorubicin—testicular cancer	2.71e-05	0.000181	CcSEcCtD
Dasatinib—Nausea—Epirubicin—testicular cancer	2.63e-05	0.000176	CcSEcCtD
Dasatinib—Vomiting—Doxorubicin—testicular cancer	2.6e-05	0.000174	CcSEcCtD
Dasatinib—Rash—Doxorubicin—testicular cancer	2.58e-05	0.000173	CcSEcCtD
Dasatinib—Dermatitis—Doxorubicin—testicular cancer	2.58e-05	0.000173	CcSEcCtD
Dasatinib—Headache—Doxorubicin—testicular cancer	2.56e-05	0.000172	CcSEcCtD
Dasatinib—FYN—Innate Immune System—KITLG—testicular cancer	2.53e-05	0.000217	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—H2AFZ—testicular cancer	2.52e-05	0.000216	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—KITLG—testicular cancer	2.52e-05	0.000216	CbGpPWpGaD
Dasatinib—LCK—Signaling by NGF—KIT—testicular cancer	2.52e-05	0.000216	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—STK11—testicular cancer	2.51e-05	0.000215	CbGpPWpGaD
Dasatinib—BLK—Immune System—KITLG—testicular cancer	2.5e-05	0.000214	CbGpPWpGaD
Dasatinib—FGR—Immune System—KITLG—testicular cancer	2.49e-05	0.000213	CbGpPWpGaD
Dasatinib—LYN—Immune System—BCL10—testicular cancer	2.48e-05	0.000212	CbGpPWpGaD
Dasatinib—ABL1—Immune System—BCL10—testicular cancer	2.47e-05	0.000211	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—KITLG—testicular cancer	2.47e-05	0.000211	CbGpPWpGaD
Dasatinib—LYN—Axon guidance—MMP2—testicular cancer	2.47e-05	0.000211	CbGpPWpGaD
Dasatinib—CSK—Disease—FGFR3—testicular cancer	2.46e-05	0.000211	CbGpPWpGaD
Dasatinib—YES1—Adaptive Immune System—FGFR3—testicular cancer	2.46e-05	0.00021	CbGpPWpGaD
Dasatinib—ABL1—Axon guidance—MMP2—testicular cancer	2.46e-05	0.00021	CbGpPWpGaD
Dasatinib—CSK—Immune System—KIT—testicular cancer	2.45e-05	0.00021	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—FGFR3—testicular cancer	2.45e-05	0.000209	CbGpPWpGaD
Dasatinib—FYN—Immune System—BCL10—testicular cancer	2.45e-05	0.000209	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—H2AFZ—testicular cancer	2.44e-05	0.000209	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—KITLG—testicular cancer	2.44e-05	0.000208	CbGpPWpGaD
Dasatinib—FMO3—Metabolism—STK11—testicular cancer	2.43e-05	0.000208	CbGpPWpGaD
Dasatinib—SRC—Signaling by NGF—FGFR3—testicular cancer	2.43e-05	0.000208	CbGpPWpGaD
Dasatinib—Nausea—Doxorubicin—testicular cancer	2.43e-05	0.000163	CcSEcCtD
Dasatinib—FYN—Adaptive Immune System—KITLG—testicular cancer	2.43e-05	0.000208	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—STK11—testicular cancer	2.43e-05	0.000208	CbGpPWpGaD
Dasatinib—FYN—Axon guidance—MMP2—testicular cancer	2.43e-05	0.000208	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—KITLG—testicular cancer	2.41e-05	0.000206	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—INSL3—testicular cancer	2.39e-05	0.000204	CbGpPWpGaD
Dasatinib—STAT5B—Disease—FGFR3—testicular cancer	2.39e-05	0.000204	CbGpPWpGaD
Dasatinib—STAT5B—Immune System—KIT—testicular cancer	2.37e-05	0.000203	CbGpPWpGaD
Dasatinib—YES1—Developmental Biology—MMP2—testicular cancer	2.36e-05	0.000202	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—BCL10—testicular cancer	2.35e-05	0.000201	CbGpPWpGaD
Dasatinib—YES1—Innate Immune System—KIT—testicular cancer	2.35e-05	0.000201	CbGpPWpGaD
Dasatinib—JAK2—Immune System—BCL10—testicular cancer	2.32e-05	0.000199	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—KITLG—testicular cancer	2.32e-05	0.000199	CbGpPWpGaD
Dasatinib—JAK2—Axon guidance—MMP2—testicular cancer	2.31e-05	0.000197	CbGpPWpGaD
Dasatinib—ERBB3—Disease—H2AFZ—testicular cancer	2.3e-05	0.000196	CbGpPWpGaD
Dasatinib—MAP3K3—Immune System—FGFR3—testicular cancer	2.29e-05	0.000196	CbGpPWpGaD
Dasatinib—KIT—Innate Immune System—FGFR3—testicular cancer	2.29e-05	0.000196	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—KITLG—testicular cancer	2.29e-05	0.000196	CbGpPWpGaD
Dasatinib—CSK—Disease—KIT—testicular cancer	2.26e-05	0.000193	CbGpPWpGaD
Dasatinib—YES1—Adaptive Immune System—KIT—testicular cancer	2.26e-05	0.000193	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—KITLG—testicular cancer	2.25e-05	0.000192	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—KIT—testicular cancer	2.25e-05	0.000192	CbGpPWpGaD
Dasatinib—SRC—Signaling by NGF—KIT—testicular cancer	2.23e-05	0.000191	CbGpPWpGaD
Dasatinib—BTK—Immune System—FGFR3—testicular cancer	2.23e-05	0.000191	CbGpPWpGaD
Dasatinib—KIT—Adaptive Immune System—FGFR3—testicular cancer	2.2e-05	0.000188	CbGpPWpGaD
Dasatinib—STAT5B—Disease—KIT—testicular cancer	2.19e-05	0.000187	CbGpPWpGaD
Dasatinib—PDGFRA—Innate Immune System—FGFR3—testicular cancer	2.17e-05	0.000185	CbGpPWpGaD
Dasatinib—ERBB3—Disease—KITLG—testicular cancer	2.11e-05	0.000181	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—KITLG—testicular cancer	2.11e-05	0.00018	CbGpPWpGaD
Dasatinib—MAP3K3—Immune System—KIT—testicular cancer	2.11e-05	0.00018	CbGpPWpGaD
Dasatinib—PDGFRA—Adaptive Immune System—FGFR3—testicular cancer	2.08e-05	0.000178	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.08e-05	0.000178	CbGpPWpGaD
Dasatinib—BTK—Immune System—KIT—testicular cancer	2.05e-05	0.000175	CbGpPWpGaD
Dasatinib—HCK—Immune System—FGFR3—testicular cancer	2.05e-05	0.000175	CbGpPWpGaD
Dasatinib—LCK—Immune System—BCL10—testicular cancer	2.04e-05	0.000174	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—KITLG—testicular cancer	2.02e-05	0.000173	CbGpPWpGaD
Dasatinib—YES1—Immune System—KITLG—testicular cancer	2.01e-05	0.000172	CbGpPWpGaD
Dasatinib—PDGFRA—Innate Immune System—KIT—testicular cancer	1.99e-05	0.00017	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—FGFR3—testicular cancer	1.95e-05	0.000167	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—FGFR3—testicular cancer	1.93e-05	0.000165	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—FGFR3—testicular cancer	1.91e-05	0.000163	CbGpPWpGaD
Dasatinib—PDGFRA—Adaptive Immune System—KIT—testicular cancer	1.91e-05	0.000163	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—FGFR3—testicular cancer	1.9e-05	0.000163	CbGpPWpGaD
Dasatinib—HCK—Disease—FGFR3—testicular cancer	1.89e-05	0.000162	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—FGFR3—testicular cancer	1.88e-05	0.000161	CbGpPWpGaD
Dasatinib—HCK—Immune System—KIT—testicular cancer	1.88e-05	0.000161	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—FGFR3—testicular cancer	1.87e-05	0.00016	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—KITLG—testicular cancer	1.87e-05	0.00016	CbGpPWpGaD
Dasatinib—BLK—Immune System—FGFR3—testicular cancer	1.86e-05	0.000159	CbGpPWpGaD
Dasatinib—FGR—Immune System—FGFR3—testicular cancer	1.85e-05	0.000158	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—FGFR3—testicular cancer	1.84e-05	0.000157	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—H2AFZ—testicular cancer	1.82e-05	0.000156	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—STK11—testicular cancer	1.81e-05	0.000155	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—FGFR3—testicular cancer	1.81e-05	0.000155	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—FGFR3—testicular cancer	1.81e-05	0.000155	CbGpPWpGaD
Dasatinib—SRC—Immune System—BCL10—testicular cancer	1.8e-05	0.000154	CbGpPWpGaD
Dasatinib—KIT—Disease—H2AFZ—testicular cancer	1.8e-05	0.000154	CbGpPWpGaD
Dasatinib—KIT—Immune System—KITLG—testicular cancer	1.79e-05	0.000153	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—KIT—testicular cancer	1.79e-05	0.000153	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—KITLG—testicular cancer	1.79e-05	0.000153	CbGpPWpGaD
Dasatinib—SRC—Axon guidance—MMP2—testicular cancer	1.79e-05	0.000153	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—FGFR3—testicular cancer	1.79e-05	0.000153	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—KIT—testicular cancer	1.77e-05	0.000151	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—MMP2—testicular cancer	1.76e-05	0.000151	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—KIT—testicular cancer	1.75e-05	0.00015	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—MMP2—testicular cancer	1.75e-05	0.00015	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—KIT—testicular cancer	1.75e-05	0.000149	CbGpPWpGaD
Dasatinib—HCK—Disease—KIT—testicular cancer	1.74e-05	0.000148	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—MMP2—testicular cancer	1.73e-05	0.000148	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—KIT—testicular cancer	1.73e-05	0.000148	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—FGFR3—testicular cancer	1.73e-05	0.000148	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—KIT—testicular cancer	1.72e-05	0.000147	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—H2AFZ—testicular cancer	1.7e-05	0.000146	CbGpPWpGaD
Dasatinib—BLK—Immune System—KIT—testicular cancer	1.7e-05	0.000146	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—FGFR3—testicular cancer	1.7e-05	0.000145	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—KITLG—testicular cancer	1.7e-05	0.000145	CbGpPWpGaD
Dasatinib—FGR—Immune System—KIT—testicular cancer	1.7e-05	0.000145	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—KIT—testicular cancer	1.68e-05	0.000144	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—KITLG—testicular cancer	1.68e-05	0.000144	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—FGFR3—testicular cancer	1.67e-05	0.000143	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—MMP2—testicular cancer	1.67e-05	0.000143	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—H2AFZ—testicular cancer	1.67e-05	0.000143	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—KIT—testicular cancer	1.66e-05	0.000142	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—KIT—testicular cancer	1.66e-05	0.000142	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—STK11—testicular cancer	1.66e-05	0.000142	CbGpPWpGaD
Dasatinib—KIT—Disease—KITLG—testicular cancer	1.66e-05	0.000142	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—MMP2—testicular cancer	1.65e-05	0.000141	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—KIT—testicular cancer	1.64e-05	0.00014	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—H2AFZ—testicular cancer	1.61e-05	0.000138	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—STK11—testicular cancer	1.6e-05	0.000137	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—KIT—testicular cancer	1.58e-05	0.000135	CbGpPWpGaD
Dasatinib—ERBB3—Disease—FGFR3—testicular cancer	1.57e-05	0.000134	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—KITLG—testicular cancer	1.57e-05	0.000134	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—FGFR3—testicular cancer	1.57e-05	0.000134	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—KIT—testicular cancer	1.56e-05	0.000134	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—H2AFZ—testicular cancer	1.54e-05	0.000131	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—KITLG—testicular cancer	1.53e-05	0.000131	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—H2AFZ—testicular cancer	1.53e-05	0.000131	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—KIT—testicular cancer	1.53e-05	0.000131	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—KITLG—testicular cancer	1.53e-05	0.000131	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—FGFR3—testicular cancer	1.5e-05	0.000129	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—HPGDS—testicular cancer	1.5e-05	0.000129	CbGpPWpGaD
Dasatinib—LYN—Immune System—KITLG—testicular cancer	1.5e-05	0.000128	CbGpPWpGaD
Dasatinib—YES1—Immune System—FGFR3—testicular cancer	1.49e-05	0.000128	CbGpPWpGaD
Dasatinib—ABL1—Immune System—KITLG—testicular cancer	1.49e-05	0.000127	CbGpPWpGaD
Dasatinib—FYN—Disease—H2AFZ—testicular cancer	1.48e-05	0.000127	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—KITLG—testicular cancer	1.48e-05	0.000127	CbGpPWpGaD
Dasatinib—FYN—Immune System—KITLG—testicular cancer	1.47e-05	0.000126	CbGpPWpGaD
Dasatinib—ERBB3—Disease—KIT—testicular cancer	1.44e-05	0.000123	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—KIT—testicular cancer	1.44e-05	0.000123	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—KITLG—testicular cancer	1.42e-05	0.000121	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—KITLG—testicular cancer	1.41e-05	0.000121	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—H2AFZ—testicular cancer	1.41e-05	0.000121	CbGpPWpGaD
Dasatinib—JAK2—Disease—H2AFZ—testicular cancer	1.41e-05	0.00012	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—STK11—testicular cancer	1.4e-05	0.00012	CbGpPWpGaD
Dasatinib—JAK2—Immune System—KITLG—testicular cancer	1.4e-05	0.00012	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—FGFR3—testicular cancer	1.39e-05	0.000119	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—KIT—testicular cancer	1.38e-05	0.000118	CbGpPWpGaD
Dasatinib—YES1—Immune System—KIT—testicular cancer	1.37e-05	0.000117	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—HPGDS—testicular cancer	1.37e-05	0.000117	CbGpPWpGaD
Dasatinib—FYN—Disease—KITLG—testicular cancer	1.36e-05	0.000116	CbGpPWpGaD
Dasatinib—KIT—Immune System—FGFR3—testicular cancer	1.33e-05	0.000114	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—FGFR3—testicular cancer	1.33e-05	0.000114	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.33e-05	0.000113	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—KITLG—testicular cancer	1.3e-05	0.000111	CbGpPWpGaD
Dasatinib—JAK2—Disease—KITLG—testicular cancer	1.29e-05	0.000111	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—MMP2—testicular cancer	1.28e-05	0.000109	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—KIT—testicular cancer	1.27e-05	0.000109	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—FGFR3—testicular cancer	1.26e-05	0.000108	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—H2AFZ—testicular cancer	1.26e-05	0.000108	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—STK11—testicular cancer	1.25e-05	0.000107	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—FGFR3—testicular cancer	1.25e-05	0.000107	CbGpPWpGaD
Dasatinib—LCK—Disease—H2AFZ—testicular cancer	1.23e-05	0.000105	CbGpPWpGaD
Dasatinib—KIT—Disease—FGFR3—testicular cancer	1.23e-05	0.000105	CbGpPWpGaD
Dasatinib—LCK—Immune System—KITLG—testicular cancer	1.23e-05	0.000105	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—KIT—testicular cancer	1.22e-05	0.000105	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—H2AFZ—testicular cancer	1.19e-05	0.000102	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—STK11—testicular cancer	1.19e-05	0.000101	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—FGFR3—testicular cancer	1.17e-05	9.96e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KITLG—testicular cancer	1.16e-05	9.92e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—KIT—testicular cancer	1.16e-05	9.91e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—KIT—testicular cancer	1.15e-05	9.79e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—FGFR3—testicular cancer	1.14e-05	9.76e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—FGFR3—testicular cancer	1.14e-05	9.72e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—KITLG—testicular cancer	1.13e-05	9.69e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—FGFR3—testicular cancer	1.11e-05	9.52e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—FGFR3—testicular cancer	1.11e-05	9.48e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—FGFR3—testicular cancer	1.1e-05	9.4e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KITLG—testicular cancer	1.1e-05	9.39e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—FGFR3—testicular cancer	1.1e-05	9.37e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—STK11—testicular cancer	1.09e-05	9.34e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—H2AFZ—testicular cancer	1.09e-05	9.33e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—KITLG—testicular cancer	1.09e-05	9.29e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—H2AFZ—testicular cancer	1.08e-05	9.19e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—KIT—testicular cancer	1.07e-05	9.15e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—STK11—testicular cancer	1.07e-05	9.14e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—FGFR3—testicular cancer	1.06e-05	9.02e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—H2AFZ—testicular cancer	1.05e-05	9e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—FGFR3—testicular cancer	1.05e-05	8.98e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—KIT—testicular cancer	1.05e-05	8.96e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—STK11—testicular cancer	1.05e-05	8.95e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—KIT—testicular cancer	1.04e-05	8.93e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—FGFR3—testicular cancer	1.04e-05	8.91e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—H2AFZ—testicular cancer	1.04e-05	8.86e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—STK11—testicular cancer	1.03e-05	8.81e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—KIT—testicular cancer	1.02e-05	8.74e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—KIT—testicular cancer	1.02e-05	8.7e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—FGFR3—testicular cancer	1.01e-05	8.65e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—KIT—testicular cancer	1.01e-05	8.63e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—KIT—testicular cancer	1.01e-05	8.6e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—KITLG—testicular cancer	1e-05	8.58e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—H2AFZ—testicular cancer	9.98e-06	8.53e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—STK11—testicular cancer	9.94e-06	8.5e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—STK11—testicular cancer	9.92e-06	8.48e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KITLG—testicular cancer	9.89e-06	8.46e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—H2AFZ—testicular cancer	9.85e-06	8.42e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—HPGDS—testicular cancer	9.8e-06	8.38e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—STK11—testicular cancer	9.79e-06	8.38e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—KIT—testicular cancer	9.69e-06	8.29e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KITLG—testicular cancer	9.68e-06	8.28e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—FGFR3—testicular cancer	9.65e-06	8.25e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—KIT—testicular cancer	9.64e-06	8.24e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—FGFR3—testicular cancer	9.62e-06	8.23e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—KIT—testicular cancer	9.56e-06	8.18e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KITLG—testicular cancer	9.53e-06	8.15e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—KIT—testicular cancer	9.29e-06	7.94e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—HPGDS—testicular cancer	9.26e-06	7.92e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KITLG—testicular cancer	9.18e-06	7.85e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—FGFR3—testicular cancer	9.12e-06	7.8e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KITLG—testicular cancer	9.06e-06	7.75e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—KIT—testicular cancer	8.86e-06	7.58e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—KIT—testicular cancer	8.83e-06	7.55e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—H2AFZ—testicular cancer	8.63e-06	7.38e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—FGFR3—testicular cancer	8.62e-06	7.37e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—STK11—testicular cancer	8.58e-06	7.34e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—FGFR3—testicular cancer	8.42e-06	7.2e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—KIT—testicular cancer	8.38e-06	7.16e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—FGFR3—testicular cancer	8.16e-06	6.98e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—FGFR3—testicular cancer	8.08e-06	6.91e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KITLG—testicular cancer	7.94e-06	6.79e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—KIT—testicular cancer	7.73e-06	6.61e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—H2AFZ—testicular cancer	7.64e-06	6.53e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—STK11—testicular cancer	7.59e-06	6.49e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KIT—testicular cancer	7.49e-06	6.41e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—FGFR3—testicular cancer	7.46e-06	6.38e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—KIT—testicular cancer	7.42e-06	6.34e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—HPGDS—testicular cancer	7.39e-06	6.32e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—FGFR3—testicular cancer	7.35e-06	6.29e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—FGFR3—testicular cancer	7.2e-06	6.15e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—STK11—testicular cancer	7.12e-06	6.09e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—FGFR3—testicular cancer	7.09e-06	6.06e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KITLG—testicular cancer	7.03e-06	6.01e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—KIT—testicular cancer	6.85e-06	5.86e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—FGFR3—testicular cancer	6.82e-06	5.83e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KIT—testicular cancer	6.75e-06	5.77e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—FGFR3—testicular cancer	6.73e-06	5.76e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—STK11—testicular cancer	6.73e-06	5.75e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KIT—testicular cancer	6.61e-06	5.65e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KIT—testicular cancer	6.5e-06	5.56e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KIT—testicular cancer	6.26e-06	5.36e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KIT—testicular cancer	6.18e-06	5.29e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—HPGDS—testicular cancer	5.9e-06	5.05e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—FGFR3—testicular cancer	5.9e-06	5.04e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KIT—testicular cancer	5.42e-06	4.63e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—STK11—testicular cancer	5.37e-06	4.6e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FGFR3—testicular cancer	5.22e-06	4.47e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KIT—testicular cancer	4.79e-06	4.1e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HPGDS—testicular cancer	4.56e-06	3.9e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—STK11—testicular cancer	4.29e-06	3.67e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—STK11—testicular cancer	3.31e-06	2.83e-05	CbGpPWpGaD
